<SEC-DOCUMENT>0001144204-14-068154.txt : 20141114
<SEC-HEADER>0001144204-14-068154.hdr.sgml : 20141114
<ACCEPTANCE-DATETIME>20141114090019
ACCESSION NUMBER:		0001144204-14-068154
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141114
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141114
DATE AS OF CHANGE:		20141114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		141220755

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v394167_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (date of earliest event reported):<B>
November 14, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><B>01-12584</B></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><B>13-3808303</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Ste. 412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Address
of principal executive offices and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>617 Detroit Street, Ste. 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;(Mailing
Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;(Registrant&rsquo;s
telephone number including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name and Former Address)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2014, Synthetic Biologics,
Inc., a Nevada corporation, (the &ldquo;Registrant&rdquo;) issued the attached press release that included financial information
for the quarter ended September 30, 2014. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The
information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference
into any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01&nbsp;&nbsp;Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">(d)&nbsp;&nbsp;</TD>
    <TD STYLE="width: 97%; text-align: justify">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc., dated November 14, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 47%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>Date: November 14, 2014</TD>
    <TD>By: &nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid">/s/ C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">(d)&nbsp;&nbsp;</TD>
    <TD STYLE="width: 97%">Exhibits.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc., dated November 14, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v394167_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48pt; width: 243.75pt"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Third Quarter
2014 Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Company Completes $18.9 Million
Net Registered Direct Offering; </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Finalizes Plans for Start of Clinical
Trials in C. difficile and C-IBS --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today, November
14, 2014, at 8:30 a.m. (EST); U.S. Participants Call (888) 347-5280 or </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Join Webcast at http://www.videonewswire.com/event.asp?id=100975<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>--</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, November 14, 2014 &ndash;</B> </FONT>Synthetic Biologics, Inc.<FONT STYLE="color: windowtext"> (NYSE MKT: SYN), </FONT>a developer
of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome,<FONT STYLE="color: windowtext">
today reported financial results for the three and nine months ended September 30, 2014, and provided an operational update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We&rsquo;ve made meaningful progress
with each of the programs in our pipeline, and we look forward to reporting the achievement of several milestones in the next six
months, including the <I>C. difficile</I> and C-IBS programs entering the clinic and the MS program completing ongoing MRI brain
scan analyses,&rdquo; said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. &ldquo;With the completion of a capital
raise of $18.9 million in net proceeds with select institutional investors, we strengthened our cash position and added a new biotech
investor to our strong existing shareholder base. All of these efforts strengthen Synthetic Biologics&rsquo; position for future
growth and success, which we believe significantly increases value for our shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Programs Update</U> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prevention of <I>C. difficile (C. diff)</I>
Infections &ndash; SYN-004 Oral Beta-Lactamase Enzyme</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical drug manufacturing under cGMP
guidelines commenced in the third quarter with a vastly improved process utilized by supplier Evonik.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preclinical data further validating the
SYN-004 approach were presented at two scientific forums &ndash; <B>ID</B>Week and the 54<SUP>th</SUP> Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S. Notice of Allowance for the first
composition of matter patent directly related to SYN-004&rsquo;s unique properties was issued.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase 1a and 1b clinical studies remain
on track to initiate within the next 30 days.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Topline data from Phase 1 studies expected
before year-end 2014.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Relapsing-Remitting Multiple Sclerosis
(RRMS) &ndash; Trimesta&trade; (oral estriol)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expanded efficacy and safety results from the investigator-initiated Phase 2 trial evaluating adjunctive
Trimesta in women with RRMS including positive results on cognitive and disability scores at 12 months, attesting to Trimesta&rsquo;s
unique neuroprotective properties, were presented at the ACTRIMS-ECTRIMS meeting in Boston in September by the trial&rsquo;s lead
investigator.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A separate Phase 2 trial focused exclusively on cognition utilizing Trimesta with a variety of
currently marketed MS drugs, including Copaxone&reg;, Avonex&reg;, Betaseron&reg;, Extavia&reg;, Rebif&reg;, Gilenya&reg;, Aubagio&reg;
and Tecfidera&reg;, is enrolling patients at four sites in the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Active discussions with a number of potential strategic partners may accelerate development of
this innovative therapy for relapsing-remitting MS in women.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">MRI brain scan analyses are ongoing to evaluate changes in the brain that correlate with improvements
seen in clinical outcomes; topline data expected during the first quarter of 2015.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Constipation-Predominant Irritable Bowel
Syndrome (C-IBS) &ndash; SYN-010 Statin-Class Oral Compound</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Strengthened Clinical Advisory Board (CAB)
to support the development of SYN-010; CAB is comprised of prominent gastrointestinal (GI) key opinion leaders: Mark Pimentel,
M.D., (Chair), William Chey, M.D., Gail M. Comer, M.D., Anthony J. Lembo, M.D., and Philip Schoenfeld, M.D., MSEd, MSc.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In September, announced the SYN-010 statin-class
formulation at an IBS Investor Day in New York. Keynote speaker, Dr. Pimentel, provided an overview of the clinical development
strategy for clinical candidate SYN-010.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anticipating a 505(b)(2) regulatory pathway
for SYN-010, a corporate Investigational New Drug (IND) application is expected to be filed with the FDA in the first quarter of
2015 with the initiation of a Phase 2 clinical trial of SYN-010 in C-IBS anticipated in the first half of 2015.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pertussis (Whooping Cough) &ndash; SYN-005
Monoclonal Antibody (mAb) Combination</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SYN-005 was granted U.S. Orphan Drug Designation
by the FDA for the treatment of Pertussis.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increased awareness of SYN-005&rsquo;s
novel mAbs combination designed to target and neutralize pertussis toxin were the topic of an oral presentation at ICAAC. Neutralizing
pertussis toxin is anticipated to decrease morbidity and mortality in critically ill infants.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An IND is expected to be filed in 2015,
with plans to initiate a Phase 1 clinical trial in second half of 2015.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Three and Nine Months Ended September
30, 2014 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1.2 million and $4.2 million for the three and nine months ended September 30, 2014, respectively, compared to $1.9 million and
$4.3 million for the same periods in 2013. These decreases of approximately 36% and 3%, respectively, are primarily the result
of bad debt expense of $763,000 associated with the note and interest receivables from the sale of Adeona Clinical Laboratory that
were determined uncollectible during the quarter ended September 30, 2013, which, for the nine months ended September 30, 2014,
was offset by supplemental compensation granted by the Board of Directors to executive officers and increased stock-based compensation
expense. Non-cash charges related to stock-based compensation were $377,000 and $1.3 million for the three and nine months ended
September 30, 2014, respectively, compared to $264,000 and $916,000 for the same periods in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $3.7 million and $9.2 million for the three and nine months ended September 30, 2014, respectively, compared to $1.5 million
and $3.8 million, for the same periods in 2013. These increases of 150% and 144%, respectively, are primarily the result of increased
program costs associated with expanded research, clinical development and manufacturing activities within our pathogen-specific
pipeline, including the Company&rsquo;s <I>C. difficile</I>, C-IBS and Pertussis programs. Non-cash charges related to stock-based
compensation were $232,000 and $550,000 for the three and nine months ended September 30, 2014, respectively, compared to $74,000
and $286,000 for the same periods in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $1,000 and $97,000 for
the three and nine months ended September 30, 2014, respectively, compared to other expense of $3,000 and $27,000, for the same
periods in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">Cash at
September 30, 2014 was $3.3 million compared to $14.6 million at December 31, 2013. In addition, on October 16, 2014, Synthetic
Biologics closed a registered direct offering with </FONT>select institutional investors for net proceeds of approximately $18.9
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Thursday, November 14, 2014, at 8:30 a.m. EST, during which Mr. Riley will provide an operational update and C. Evan
Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the three and nine months
ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested parties should call 1-888-347-5280
(U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the
call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question &amp; Answer Session.
The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=100975. If you are unable to participate
during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=100975,
for 30 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus
on protecting the microbiome. The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the
effects of intravenous (IV) antibiotics for the prevention of<I> C. difficile</I> infection, an oral treatment to reduce the impact
of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination
for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting
multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding advancing Synthetic Biologics&rsquo;
clinical programs and achieving milestones, the ability to achieve future growth and success and increase shareholder value, and
the anticipated timing of the Synthetic Biologics&rsquo; clinical trials, filing of INDs and release of results. The forward-looking
statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or
implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected
in Synthetic Biologics&rsquo; forward-looking statements include, among others, a failure to receive the necessary regulatory approvals
for commercialization of Synthetic Biologics&rsquo; therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials, and
those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure of Synthetic Biologics&rsquo;
clinical trials to receive anticipated funding, a failure of Synthetic Biologics&rsquo; products for the prevention and treatment
of diseases to be successfully developed or commercialized, Synthetic Biologics&rsquo; inability to maintain its licensing agreements,
or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products and other factors described
in Synthetic Biologics&rsquo; report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The
information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to
update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except
as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics: Kris Maly, VP, Corporate
Communication, (734) 332-7800, info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media: Wendy Emanuel, Wellspring Communications,
Inc., (773) 255-9580, wendy@wellspringcom.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>(in thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">2013</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(Audited)</TD><TD STYLE="padding-bottom: 1pt; font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,286</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">14,625</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,382</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,591</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,741</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">984</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Synthetic Biologics, Inc. and subsidiaries equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,757</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,741</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Condensed Consolidated Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the three months ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the nine months ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,218</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,890</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,154</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,270</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,693</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,475</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,247</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,796</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,911</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,365</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,066</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,911</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,365</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,066</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Other income (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income (Expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">97</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,910</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,368</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,304</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,093</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to <BR>Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,910</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,368</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,304</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,093</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.08</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,453,528</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,654,414</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,356,025</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">44,636,935</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_X0O$17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````H@```,X`#T)````G
M$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,3(Z
M,3@@,3`Z,C@Z,34```.@`0`#`````0`!``"@`@`$`````0```D^@`P`$````
M`0```8H`````````!@$#``,````!``8```$:``4````!```!'`$;``4````!
M```!)`$H``,````!``(```(!``0````!```!+`("``0````!```*CP``````
M``!(`````0```$@````!_]C_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#
M`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``?`*`#`2$``A$!`Q$!_\0`'P``
M`04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0`
M``%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!
M`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W>\OH+&,-,QRQ
MPJJ,EC["JIU"^DB,EOIC.,C:'E"$CUZ'V_.HJ.48-Q5WV*@HN24G9!_:WDJS
M7ME<6JHNYG(#IU`QE23W]*O0SQ7,2RP2I+&WW71@P/XBBE.4X\SBUZE5*?)L
M[KNB2L'Q5XLT_P`):<EU>[Y))6*PP1XWR'OU[#C)[9'J!5F9S5O\47MK^WM_
M$7AR^T:.Y($4TK$KG(R3N5<`9&<9QZ5LZ'XV@U7Q%>Z#=V4FGZC;=(I7SYH'
M4KP,\8(]0<C@4`5;CXAVZZYJNFV>G372Z7;RSW-P)`JKY:Y8#/).<+]?89J]
MX.\:V/C&UN'MXGMY[=@)()#D@'HP(Z@X(_#Z9`,U_B([S:O#9>'[Z]ETV\%J
MZ6_SLV3(-^`#@?N__'A6;!\69+J]ELK?PIJ<UW%GS((_F=,'!RH7(P2!0!N:
M5X[34O%2Z`^EW%K<_9TG<RM@H6C5]I7&01NQ^%7-?\6PZ!K>C:9):/,VIS")
M75@!&=RKDCO][]*`.<B^*<MW=W5O8>%M3O3;.4D-N"^WD@9PIQG!_*K0^(&J
M&!Y/^$(UP%650ODMDY!Y^[VQ^M`%*V^*T]Y<3V]KX2U6>>!MLT<0+-&<XPP"
MY!R#U]*V=,\=QZAXK3P^^F3VUP;=)W,K8*%HEDVE<9!&[!]Q0!F7GQ1$M]-;
M^'?#]]K:0'$LT`8(">F,*Q(.#R<=#C-=!X2\9:?XOM9I+2.6&>W*B:&4<J2.
M""."."/7CH*`)M151K]L\H_=^6,$CC@G/Z5N4`%9%YIDEK(]]I`$=R2#)!G$
M<X]QT!_VAS]<U479Z[%PE9V>S+6DZI!J]A'=VYX8#<A8$H2`0#@]P01[$'O7
M)?$;3M#U;^R;+4=4?3=2DF(T^98G<%B5#*<<#G9R2,<'.,YGT%.+A)Q9RWB&
MZ\7^$[6UE\3II'B'2C,(U2>)7*M@D<E00Q4-\Q##KGWO?%&S%O;:7XTTF9[2
M^1D0NH*LZLI*D^XY!!'(;!X&*"2YH'AZ#0_@_J4Z$/<ZAI<MU-)CG#0DJOK@
M`_F6/>N0T>RN?"_AG0?'6EH7"^9#J4.\@2(964'^0]B$.#S0!U7PLNX;_P`2
M>,[RW;?!<7B2QM@C*L\Q!P>G!JCX&_Y+/XG_`-VY_P#1Z4`4=7M];N?C;J4?
MA^\@M+_RD(EF`*[?)3(Y5OY5'K=GXIM/''A(>)M2M;UFOH_(-NH&T>8F[.$7
MV]:`*W@NS\5W>L>(?^$8U*TLMMPOVC[0H._+2;<?(W3YO3K7KOABV\06NFR)
MXDO;>\O#,2DENN%$>%P/NKSG=V[T`<7\.O\`DH'C7_K\;_T;)6%KR22?%CQ,
MD2LTC:5,$5!DD_9!@#'>@#K_`(0RV+^!8H[4K]H2:3[4!G.\G@G_`(!LY'''
ML:T=#U7PW=^,=5L]+T[9J4`?[5=I`JJYW`,-P.2=WJ.=IH`Z&_M&N[<K%((9
MQ_JY=N2GKC\*PK;6[C2KC[)K"N"3A'Z@XZE3_$.1[CTKAQ,YTJD:M_=V:_4B
M3<7?H;]M?VEYC[/<1R$C.T-R![CJ*CO]4LM,CWWEPL0*EE!ZL!C.!W/(XKNI
M-5K>SUN34K4Z<'4F[)'%_#:.Y6[URXQ$UA=W`EA:WD0Q*W)8;`Q*$ADX(S@#
M-;WBW1-`U^R2TUMUC,:O-%,'"/$JXWL">B\KG/'3/:IA"<%RS5FCT,=6HUZS
MJT'>+2_)7_$R8OA=I#7%K)?ZCJNI0VO$-O>7(>-1C&,``XX'`('`SQQ6_P")
M/#UCXKTLZ;>33)$LJN3`P#!@.!R#V/I5'(/FTNQMO"O]BS3O'9?9!8^8S`.5
M*B,<XQN.0!QR2..U1Z%H>F:?X731;61KO3U66(^:P8L&9MZM@`=2P(QQC%`%
M/PKX.TKP=+=1V%S<R/>!69;AU)PF>5PH_O\`/X4_2?!>G:/XGO\`7[>:Z:ZO
M0XD21U*#>P8X`4'J!W-`$<7AW1H_'4^OI>RG4Y`(7A,B^6#Y:_+C&=VP!L9S
M@YZ5:UKPI8Z[JVE:E=2W"3:;*)85B90K'<K?-D$D94="*`.3;X3>%=1O;B1-
M3U%Y68R.J31\9)_V.F01^!]*Z+PUX0TGP-!?SVMU<F*95>9[J12$5`QSD*,#
MYCG-`%K1?"=AH6L:IJ=K+<O/J4ADF65E*J2Q;Y<`$#+'J359?#6CP>.G\0?;
M)AJ<RA/(,B[/]7MP!MSG:A/7L3T%`&7??"C0+J^FNK6:^TXS`B2*SE"H0?O`
M`J<`^G3VK:\*>']#\-VTUCI!#R9#7$CL&E?D@%B,<`A@,`#(;OF@#H*BN(8;
MB%HKB))8SU1U#`_@:32:LP.2OM!T!+A8Q=7EJ3P$C<L#_P!]*V*F3P7I]U8>
M1<7=U,O_`"S<%4*`G)&`,'/<D$\#TK/"T8X6K[6EN<5?`TJT7&5[,Z.PT^TT
MRS2ULH$@@3HB#]3ZGW-5=4T.UU=B;AI`3:S6OR$#"R[-Q&0?F&P8/UZUM*3D
M[O<ZXQ48J,=D:=,2)8WE<$YD8,<^N`/Z4BAES`;B'8LK1L&5PP`/*D'!!['&
M#WP3@@\TVQLTL;<PHS,&EDE);'WG<N>G;+''MZT`.:W1KR.Y);?'&\8';#%2
M?_01^M34`4#IBM=Q3-.Y2&=KB*/`^5V1D(SC)7YV..N3UQ@"_0!GZ=I*Z:(8
MXKB<V\$(@AA+?*J#&,^K#&,^GODFQJ%E'J.FW5C,S+%<PO"Y0X8!@0<9[\T`
M6*IQZ>(+Z:XBF=%GD$LT>`0[!`@Y/085>!W`Z<@@%RJEG8)9SSR(YQ*<[``J
M@[F8G`XW$L<MC)`7.2,D`__9`/_M$GQ0:&]T;W-H;W`@,RXP`#A"24T$)0``
M````$``````````````````````X0DE-!"\``````$K;`0$`2````$@`````
M`````````-`"``!``@`````````````8`P``9`(````!P`,``+`$```!``\G
M`0!L;'5N`````````````#A"24T#[0``````$`!D`````0`!`&0````!``$X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24T$"@``````
M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L
M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``````
M`0`U`````0`M````!@```````3A"24T#^```````<```________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!#``
M``````(!`3A"24T$+0``````!@`!````!CA"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-)````!@``````
M```````!B@```D\````*`%4`;@!T`&D`=`!L`&4`9``M`#$````!````````
M``````````````````$``````````````D\```&*````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```&*`````%)G:'1L;VYG```"
M3P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG```!B@````!29VAT;&]N9P```D\````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``````
M```X0DE-!!0```````0````'.$))300,``````PP`````0```*````!K```!
MX```R*````P4`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I)
M)))2DDDDE*22224I))))3__0]522224I))))2DDDDE*22224I))))2DDDDE*
M22224I))))2DDDDE*22224__T?54DQ(`D\*BSJ-N386X=.^MI@W/.UO]AL.<
MY)3?25`V]:9N+L>BYLG:&6N:Z.W\Y5L_Z:G5U7&=D?9;@_&R"2&5W#;OCO19
M[JK_`/K=GJ)L)<5T)"M[C**\XY#727]TB7X-Q))5>I]0Q^F=/R.H9,^CBUNL
M>&B7$-'T6#3WO^BQ.6-I)<+_`,]OK9^S_P!N?L*H]'C?(R)MV3L]71N[9N_[
MK_R_YG]*K;/K\T=4Z?7?C"KI'5ZVOP\YSB'!SHK=1DT%FQEE&3^@OV7O9^FH
MN_F_424]>DN;ROK7<?K33]7.EXS<IX`=G9#GEK:&Z/L]K:W[W5U.K_/9^FR<
M>G_2>G7^J'U[K^L.39AY..W#RMGJT,;87BQ@_G1N<RK]+5[?9_H_^+L24]8D
MN0_YX]<R,SJN'TSI+,R[IF2RD,%X875N.0UU[O58UK-CL>O]'[_YU5*/KU]:
M<G,R,#&Z`RW-Q/Z10,IH+.VKGUMK=S_@WO24]TDN;Z/]:<W.^L=_0\K#;C/Q
ML5F18X6;W"QS,6RR@MV;/T;\M[/4;9_@E+JGUIOP?K/C=#;C-LKR,9^0;R\A
MP+695GI^GL=_W#^EO_PB2GHDEPW3/KO];.JX@S.G_5YF303M+VY36C<`"YNV
MUE;_`&[E;R?K+]<\?'9D.^K@#6U/MR2<ID5['6:<'?\`H*V7>W_2)*>N27'=
M#^N'UEZP_&NHZ&T].NM%=N8W(:0QH=LNL]*QE=C_`$OZJ73O\8=-GU:R.N]0
MQA0:LC[-3CU/WFQYKKO8&OL;3L_G'^I_HZJO424]BDN&M^NWUKP\5O5NH=`%
M72'02X7#U6,=]!]C7@.;_P!>HQ_^$]%=CT_/Q>I8-&?B/]3'R6-LK=Y.$P[]
MU[?HO8DI_]+U'(K=9CVUM^D]CFCXD0JO1S^IM:6EI&L'_-/_`$V.5Y974NF9
M1R#G8+YO@;J7&`0WZ/I/_P`'9_QGZ*W_``B9EG.,;C#CUUC='A\$$UTMU4+*
MQ<?+I=1DUMMJ?RUP_$?NN;^:]95'UEH;9]GSV.QL@<M<T@_'TS[_`/MGUZ_^
M$5P]:Z;Z=CVW!_IL=8Y@!W;6\Z.V_P!5#'GQS($9>HFN$^F?%VX4>[$:\0%:
M[U5-7!SG874OV)FY`ML>WU,%[R?5LK_2;J[?;LLLQVT_SV_])_A/?[["_67)
MP,7H6;=U+'LR\$5[<FBH`O-;R*K")?3M]-K_`%'V>JSTV?I%SF1DCK_ULP+,
M%[F'ISMQ:YKBTU_2LLWU-<VCU8]#9?9_H/\`A]G6]0RJ,3"MR,AN^EC?>T09
M!.R/TA97^=_A';%+*,XR(G'A.E>,2RRG@R8\67#D&3W(GW*_0R1EP_U?F^9\
MY9T]F!T5W6_JU]9;L;'8SUAT_*>PN#XW/Q7UAQQ_M>[]'Z?V6[UK?\)_A5L9
MG_93_BY/4NI,:,NBF[)KL:(!?C&UGJ-9/\WF4U;;&?N7^S_!J_A?4WZD]1:W
MJ-72JAO<\;22&2QSJGM]&JQV+Z>]COYO]"];M]>"]@Z/94#1D8]C?1`BOT6>
MG195[=NSVY#&L:U!8\W_`(MNFTU]&=UAY-N;U.RQUUKR7.VUV64MKWN)<[<]
MMF18_P#PEMW]1<CT#HV9D_5/]M]*);U?HV:^VC:)=94*L=UM!`]UG+WLK_PG
MZ?&_[5+T^JCIW0NF&O&J]##Q@YS::P7:N<;'-K;JYS[+;/\`/0?J_A]*P<6[
M%Z9AG`;7<?7QC$MM+*W27,?=6[?0:'?H[7_]N>HDIY7_`!<YC,_KG7\]C=C,
MPT7M:3NC>[)=MW#Z2)]5?_R@_6+X?]^8NEP^F=$Z-F'[#B-QKNI.(>ZH0'%@
MLR/<)VL;[K=NQ'Q>B]*Q,_(ZCC8[:\S+_I%PG<_6?=KY)*>%NZ5D]5_QB]7Q
M<;.NZ:]M3;#D8Y(>0*\)GHF"S]&[U-__`%M!NZ7D]*^O.#BY.==U*QV'=8,C
M()+P'4=09Z(ES_T;/3W_`/7%VF(SHHZ[=G48;J\W*+\9W4"/;:ZG8V[';[R[
M=7]E_/IKW_9;/35CJ'2NB')/6\ZAAR,2E[?M)W%S:0VWU6PW_@[[_P`W\])3
MYO\`5#$KNZ,Q[OK._H9#R/L;;:ZP=&?I]EKV/_2+NV>DWZGY5574?VOZ6-D,
M=G;VV%[MMCCO?6Y[=S-VQ5<#ZH_4W,8^.CLI=2[TWUV$%P,-=_@;KF?G?O[U
MK5=-Z/TO#9TK'QA5B9KWU&EDEI-C+++=\NW;7UUO24XO^*__`,2=7_'7?]65
MY_11;_S*IS=AMQ\/JV[(8.-KL?%:QS_S6M<_]7]W_<A>Q=-Z9T_I.(,3I]+<
M;&:2X5MF`7>YY]Q*H]`PNBUX%N+T_IQQ<#)`M++&@UW,M;Z?J;2^[^<IJ;ZE
M-WIV_P"FI24AZI]<_J_B]%?U*O(IS&N9-6,U[0^PG_!.K=[ZO^']6O\`0?X5
M:/0\QV?TG%S78WV+[16+!C$@EK7>ZN=K6?39^D^BL;*^J7U,Z2#U-W2F.-;F
M^T2Y@)<&M=Z5]GV2JNN=WJ6^G32NCHN;?17>T%K;6AX!B0'#=KM+FI*?_]/U
M5))))37R\>O(J-=U%>0SG9:`6S_::]9]'U<Z6VP7?8VT6#_16V`1^[M8:F;/
MY&Q;"2!C$FR`3Y(,0=P"AQL3&Q6N;C5,I:]V]S6`-!=`;NVM_JI\G'IRJ747
M-W5OB0"6G0[FEKV%KV.:X?2:BI)Q))LZJ``%`4/!%C8M&+5Z-#=K)<XR2XES
MR7V/>]Y<][WO=NW/4C34;FWELVL:YC7>#7ECK&_VG4UJ:2"4=]%612^B]HLJ
MM:6/8>"TZ."CBXE&(PLI!&]V][GN<][G0&[K+;7/ML=L:QGO?_-L]-&224@R
ML+'R_3-P=NI=OK<Q[ZW`D%A]]+JW_1<CI))*:M?3,*K+=F,KBYVXSN<6@OCU
M7UTEWHUV6[?TME=>^S\]6+*V6,=78T/K>"U['"00='-<T_2:Y2224UL/IV)A
M;_L["#:0;'/>^QSMH]-FZRYUC_8P;46RFJUU;K&[G4NWUGP=M=7N_P`RQZ(D
MDI2K8?3L/!+CC5[-X:TRYSH8S=Z5-?J.?Z5%6]_I45?H:O\`!L5E))2+)QJ<
MJKTK@2V0X%KG,<"#+7,MJ<RQG]AZ?'QZ<:BO'H8*Z:FAK&#@`(B22G__U/54
MDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]7U
M5))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))3__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`S`````0`X0DE-!`8```````<`"`````$!`/_A#]!H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M
M8S`S-B`T-BXR-S8W,C`L($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@
M("`@(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+R(@>&UL;G,Z>&%P34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.G1I
M9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X87`Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#
M4S,@5VEN9&]W<R(@>&%P.D-R96%T941A=&4](C(P,3$M,3(M,3A4,3`Z,C@Z
M,34K,#$Z,#`B('AA<#I-;V1I9GE$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87`Z365T861A=&%$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87!-33I$;V-U;65N=$E$/2)U=6ED.C-$,$$Q-#%$-4$R.44Q
M,3$Y0D4S041#13A",C)"-C8R(B!X87!-33I);G-T86YC94E$/2)U=6ED.C-%
M,$$Q-#%$-4$R.44Q,3$Y0D4S041#13A",C)"-C8R(B!P:&]T;W-H;W`Z0V]L
M;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV
M-BTR+C$B('!H;W1O<VAO<#I(:7-T;W)Y/2(B('1I9F8Z3W)I96YT871I;VX]
M(C$B('1I9F8Z6%)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z65)E
M<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z4F5S;VQU=&EO;E5N:70]
M(C(B('1I9F8Z3F%T:79E1&EG97-T/2(R-38L,C4W+#(U."PR-3DL,C8R+#(W
M-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y
M+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S,CLT1#,X,$(Y1#@V
M0T4P,41",C8X1CDW,#9$1$5!0C)!,R(@97AI9CI0:7AE;%A$:6UE;G-I;VX]
M(C4Y,2(@97AI9CI0:7AE;%E$:6UE;G-I;VX](C,Y-"(@97AI9CI#;VQO<E-P
M86-E/2(Q(B!E>&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L
M,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X
M-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L
M,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S
M.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L
M-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y
M.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L
M-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q
M+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X
M+#,P.T,U,D5%,30W-3<Y0C,S03E&,#`T,S<U-38T,#8Q-D1$(CX-"@D)"3QX
M87!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C<T,D4X
M-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B!S=%)E9CID;V-U;65N=$E$
M/2)U=6ED.C<T,D4X-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B\^#0H)
M"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX;7!M971A
M/@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,`
M`@$!`@$!`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*
M#0H*"PP,#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`&X",P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/W\HHHH`****`"C-9VK>,-)T`D7^J:=9$<D3W*1X_[Z
M(K-OOBYX8T[PU?ZS-KVF+I6F?\?-TLZM%&>PR,Y8]@,DY``R145*D:<'4J.R
M6K;T27=LNG3G4DH4U=O1):MOLD='FBN%T#]IGX>>)[.WFM/&OAG-RH=(I=1B
MAF`*[L&-V#`@=01D<^E=CIFLV>MV_G65W;7D6<;X95D7\P:Y\+F&%Q*OAZD9
M_P"%I_DSHQ.`Q.'=L13E#U37YHLT49HS76<@449HH`****`"BBB@`HHHH`**
M**`"BF7%Q'9V\DTTB111*7=W8*J*!DDD]`!WKQ?QS_P4?^`7PWNIK?6/C#\.
M[>ZMSB6"+7(+B:,Y`P4B9F!Y!P1G'/3F@#VNBO%?!7_!1SX!_$6[AMM'^,7P
MZN;JXQY4$FNV\$TA]`DC*Q/'3&?:O9K.\AU&TCN+>6*>"90\<D;!D=3T((X(
M/J*`)**JZKKMCH4:/?7MI9)(<*T\JQACZ#<1FJ/_``L/P_\`]!S1_P#P-C_Q
MH`V**AT_4[;5[59[2X@NH'R!)$X=#CKR.*FH`***S]3\6:5HMR(;W4]/M)B-
MP2:X2-L>N"<XH`T**Q_^%AZ!_P!!S1__``,C_P`:EO/&VBZ?<-#<:OI<$R8W
M))=1JRY&>03Z4`:=%9VG>,-(U>[6WM-5TVZG<$B.&Y1W..O`.:T:`"BBJ>K>
M(=/T'R_MU]9V7FYV>?,L>_&,XW$9QD?F*`+E%94/CW0KF9(X]:TF221@JJMW
M&68GH`,\FGW_`(RT?2KM[>ZU73;:>/&Z.6Y1'7(R,@G(X(/XT`:5%8__``L/
MP_\`]!S1_P#P,C_QH_X6'X?_`.@YH_\`X&1_XT`;%%8__"P_#_\`T'-'_P#`
MR/\`QH_X6'X?_P"@YH__`(&1_P"-`&Q16;8^--&U.Z2"VU;3+B>0X2.*Z1W;
MC/`!R:;=>.-$L;F2&?6-+AFB8JZ/=QJR$=B"<@T`:E%4-,\6:5K5R8;+4]/N
MY@N[9#<)(V/7`.<5?H`***H:GXLTK1;D0WNIZ?:3%=VR:X2-L>N"<XH`OT5E
MVOCC1+ZYCA@UC2YII6"HB7<;,Y/8`')-6-5\2:=H+(M]?V5D9<E!/.L9;'7&
MXC-`%RBL?_A8?A__`*#FC_\`@9'_`(T?\+#\/_\`0<T?_P`#(_\`&@#8HK'_
M`.%A^'_^@YH__@9'_C1_PL/P_P#]!S1__`R/_&@#8HK-A\9:/<VD]Q'JNFR0
M6VWSI%N4*1;CA=QS@9/`SUJ'_A8?A_\`Z#FC_P#@9'_C0!L45C_\+#\/_P#0
M<T?_`,#(_P#&C_A8?A__`*#FC_\`@9'_`(T`;%%8_P#PL/P__P!!S1__``,C
M_P`:/^%A^'_^@YH__@9'_C0!L452'B33CI1OQ?V1L5.#<>>OE#G'WLXZ\=>M
M5/\`A8?A_P#Z#FC_`/@9'_C0!L45#8:C;ZK:)<6L\-S!)G;)$X=&P<'!'!Y!
M'X5-0`44,P12S$!1R2>`*\?^('_!0/X&_"R\EM=?^+GP\TZ\@#&2V;7;9[A,
M=08T<N#Z#&21@9-`'L&:*\/\$_\`!2W]G[XAWD=OI7QC^'DMS,2L<,^M0VLD
MAR!A5E922<\`<GMWKVK3]1M]6LHKFTGANK:=0\<L3ATD4]""."/<4`3449HH
M`****`"BBO)/VJ_C++\/?#L6DZ;*8M5U9&S(IPUM#T+#T9CD`]L,>H%-*XFR
M7XR?M3Z7\.;B73M-C35M6C^5P&Q!;GT9AU8?W1^)!KP#Q9\<?%_Q$NC'/JEX
M$E.%M;/,4?TVKRW_``(DUR^BZ//K^IQ6L`S)*>IZ*.Y/M7T)\#_@3;SQ"9U*
M6L9VRS8Q)<-W4>B_YZY-:62)NV>0>'/@KK7B295$1C=^=@4RR?7"_P!37HGC
MS]D&_P#C;X;TG3M<EO\`3K?2$V6PL98X+<9ZN]N=RF0YY8;2>^:^B]*T>UT.
MT$%I;Q6\2_PH,9]R>Y]S5FO,S7+<+F.&EA,;#GIRW6J_)IGH9;F.)R_$1Q6$
MFX3CLU;]3X8\1_\`!+_6-.U..&QOC>VTK;1<><H$7H74KD#/]W=]:R;K_@G5
M\0_!MR;O1KN19X^DEI<+'(/H0ZM^0K[]HK\IJ>"&1.4ITJM6%W=6E'W?)7BW
M;U;?F?H5+Q<X@BE&<HR76\;W]=?^!Y'P'#XW_:#^!3H)]4U2[MHSCR]4C-PD
M@]-\RY_[Y>O5K+_@HZOPY^&_AK5_B'X>N[:?7K^[LRVEQ$I$L"P'S=CMR"9L
M<.3\IP#R!]1R1K*C(RAE88((R"/2N&^*?[.'A/XNZ#%I^I:<D$=L9&@:U`A\
MII-N\[0-C$E5SN4]*^EX.X-QV39BIXC,)U\+9KDDG=/2S3YFM.R2^9PYGQ=E
MV:4XPQ>"A3E>[G37*VK/=*W6V]R?X0?M"^"_CQIANO"GB&PU;8NZ2!&,=S"/
M]N)L.H]R,'L:[7-?!'QF_P""8NN_#[4_[?\``6HW27-FQEAETYF@NH".X0'/
MMF-L_P"S4?P?_P""DWC7X(:G'HOQ6TN;7M+1_)75[6,)=PX./G7A9,8Z'8_4
MDL>*_6*F5*I'VF#GSKMU_K[CQ:O#\*T'5RVI[1?RO22_S_#T/OO-%<[\,OBK
MX=^,?A2'6_#.K6FL:;/P)86.4;NKJ<,C#^ZP!Y'%=%FO(E%Q=I*S/FIPE"3C
M-6:Z,****DD****`"O)_VUOVP?"_[#'[/FK_`!`\5&6:VLBMO96,+`3ZI=N#
MY5O&3P"VUB3SM1';!VXKUBOQO_X.G_B%J$GB_P"$7A-9'CTN&SO]6>,.=L\S
M/%$I9?5%1\'_`*:M30'PG^VQ_P`%,/BS^W;XFN9_%WB&YM/#ID)M/#FG2-!I
M=HH.5!C!_>N/^>DNYNN"!@#P_P`-^$=6\97YM-'TS4=5NL9\FSMGGDQC.=J@
MGH#6K\&O"NF^.OB]X4T/6+PZ=I&LZQ:6-]=;U0VT$LZ)))N;@;58G)X&*_JM
M^#?P1\)?L]^`K'PQX*\/Z7X;T/3XUCBM;*`1AL`#>Y^])(<99W)9B222235-
MV`_DWU?1+WP_>FVO[.ZL;A1DQ7$31..<=&`/4'\J]B_9`_X*%_%C]A_Q1;WW
M@7Q3>V^F)('N=#O':XTF^&<LLD!.T$]-Z;9!DX89-?TL_'O]F_P-^T_X$NO#
M7CSPSI7B32KJ-DVW4`:6W)&-\,GWXG'4.A#`CK7\W'[27_!.CXG?!3X_^,?"
M6D^`_'OB'2-`U:XL[#4[;0;F>*_MED/DRAXXRA+1[2=O`)([4D[@?LS<:MX#
M_P""_?\`P3<U&*QBCT3Q%!(1'%<$22^&];ACW(=P&6@</MW@`M%(PPK@A?P`
M\?\`@/6/A;XXU?PWK]A/I>MZ#=RV-]:3#$EO-&Q5T/T(/(X/49%?J3_P;;^$
M/B7\$_VH/&N@^)/!OC3P[X:\2^'/M+2ZEH]S:6S7EM<1"(;I$5=WESW'N?SK
MJ/\`@Y`_X)VG4+.']H#PI8YFMEBL/%\$29+IQ';WQ_W?EB?V\H]F-*X'F?\`
MP;H?\%#3\)/BG+\$/%-\5\.>-;@S^'I96RMCJ9`!@!/1+A0`!T\U5`&9&-?M
M_7\A6F:E<:-J-O>6D\MM=VDJS031,4>%U(*LI'(((!!%?TI?\$D/V^;;]OK]
ME/3]7O;B(^-_#6S2O$UNN%8W`7Y+D*.B3J-XP``PD4?<IM`>X_M!?'3P_P#L
MS_!?Q)X[\477V70_#-D]Y<$8WRD<)$@)`,DCE449&6<"OY>OVL?VF/$'[7_[
M0?B;XA>)I2VH^(+HR1P!BT=A;CY8;>//\$<851W."3DDD_>W_!Q?_P`%#!\7
MOBM%\$_"U\)/#?@BX\_Q!+"WRWNJ`$>02#ADMU)!'_/5G!&8P:_.7X3_``LU
MWXW?$K0_"'AFPDU/7_$5Y'8V-M'P9)'.!D]%4<EF/"@$G`%"0'UY_P`$-_\`
M@GA_PVM^TRFO^(['S_AW\/I(K[4UE3,6IW1)-O9\\,I*[Y!R-B;3CS%-<1_P
M6N54_P""HOQ<"@`+J%J`,8Q_H-M7[[_L+?L@Z'^PY^S/X=^'VB>7.^GQ>?JE
M\$VMJ=](`9[@@\@%@`H.=J*B\[:_`G_@MC_RE'^+O_80M?\`TAMJ$!X)\"_C
M5X@_9S^+_AWQQX6O#8Z_X9O4O;23&5)'#(X_B1U+(R]U9AWK^GS]B[]J_P`/
M_MK_`+./ASXA^'66*#5X=EY9F0/)IEVGRS6[X[JW0D#<A1L885_*OFON3_@A
MG_P49/[%G[1H\,^)=1,'PX\?S1VNH&5_W.E7GW8+SGA5Y\N0\#8P8Y\M:&@/
MZ&*_('_@ZS_YH-V_Y&'_`-Q=?KZKAU#*05;D$<@U^07_``=:?\T%_P"Y@_\`
M<720'YD?L<'_`(R[^%?;_BL-(_\`2V&O>/\`@O2?^-L/Q6_[A'_IGL:\'_8Y
M_P"3N_A7_P!CAI/_`*6PU_23\6_^"<GP.^/'Q"U#Q9XQ^&GAOQ!XCU;R_M=_
M=1N99_+B2)-Q#`?+&B*..BBFP/Y;Z*_IM_X="_LT?]$<\'_]^9/_`(NOQ!_X
M+6?!7PI^S[_P4)\5^%O!>AV/ASP_966GR06-HI$4326D3N1DD\L23[FA,#Y0
MHKZ(_P""3_PM\/?&O_@H5\-/"WBO2;37/#VKWMQ'>6-R"8KA5M)W`8`@\,JG
MKU%?O+_PZ%_9H_Z(YX/_`._,G_Q=%P/PY_X(G9'_``5'^$70_P#$PNO_`$AN
M:X__`(*@X_X>*?&GCKXPU'_T>U?T*_"[_@FQ\"?@IX^TWQ3X4^&/AK0_$.D.
MTEG?6T;B6W9D9"5RQ'*LP^AK^>K_`(*@_P#*13XU?]CAJ/\`Z/:A,#Z0_P"#
M:;/_``\3O>G_`")]_P#^C[6OWUK\"O\`@VE_Y2)WO_8GW_\`Z/M:_?6DT`5^
M!7_!RSG_`(>)V73_`)$^P_\`1]U7[ZU^!7_!RU_RD3LO^Q/L/_1]U0D!\W_\
M$OL?\/%/@MQT\8:=_P"CUK[O_P"#J?\`Y'_X,'UT_5?_`$9:U\(?\$OO^4BG
MP5_['#3O_1ZU]W_\'4__`"/_`,&/^P?JO_HRUIO<#\F:*U/!-G%J/C/2+>=%
MEAGO88Y$;HRF100?PK^EG_AT+^S1_P!$<\'_`/?F3_XNFW8#^9*BOZ;?^'0O
M[-'_`$1SP?\`]^9/_BZ/^'0O[-'_`$1SP?\`]^9/_BZ5P/Q1_8TR/^"3_P"V
MAD?]"1_Z>)J^0*_J1\,_\$Y/@=X-^'WB?PII?PT\-V7ASQG]E_MNPCC<0ZE]
MEE,MOY@W9/ER$L,$<FN;_P"'0O[-'_1'/!__`'YD_P#BZ$P/YDJ*_=+_`(+&
M_P#!.3X'?`;_`()P_$;Q9X/^&GAOP_XCTK^S/LE_:Q.)8/,U2TB?:2Q'S1NZ
MGV8U^%M-`%%?NE_P1R_X)R?`[X\_\$X?ASXL\8?#3PWX@\1ZK_:?VN_NHG,L
M_EZI=Q)N(8#Y8T11[**^F_\`AT+^S1_T1SP?_P!^9/\`XNDF!^?/AD?\<K'B
M'T_M!/\`U)K>OR8K^A7_`(+#?!7PI^S[_P`$8?B9X6\%Z'8^'/#]D^F206-H
MI6*)I-;LG<C))Y8DGW-?SU41`_H]_P"""W_*)[X4]?\`F+_^GB^KU#]O3]O7
MP7_P3[^"\OBOQ9*]W?7;-;Z-HT$@6ZUBX`!V)G.U%R"\A!"`C@LRJWEW_!!J
M58?^"37PK=V5$0:N6).`!_;%]R:_%/\`X*H_MN7G[=?[7GB'Q-'=S2>%-*E;
M2O#5L6.R&RC8A90O9YFS*W?YPN2%&$D`O[;/_!57XP_MS:W=IXC\1W6C^%9'
M;[/X;TF5K?3XD.<"0`YG8`\M*6ZG`4';7S=CL*]]_P""<G[!'B#_`(*%_M#V
MO@[2ISI>CV<7V[7=6,>]=.M`P!('1I7)"HO<G)PJL1_03^S5_P`$T_@E^RCX
M;M+'PI\/]`>\M@"^KZE:1W^J7#C&7:XD4L,D9VIM0'[JKTIWL!_+SS@5[/\`
MLD?\%`?BO^Q)XEBOO`/BN^LK'S`]SHURQN-*OAGD26[';D\C>NUQDX8$U_1O
M\?\`]@GX/?M/>&[C3?&?P^\-:D+A<+>1V:6U_`<8#1W$8652!CHV#@9!'%?S
M^_\`!5/_`()U:A_P3G_:&708KNXU?P?X@@:_\/:E.`)I8@0LD,NT!?-B8@$J
M`&5D;"[BJC=P/W+_`."9_P#P4I\*_P#!1KX12ZKIT":)XMT0K%KVA/,)'M&;
M.V6-L`O`^#M;`((93R`3]*U_,?\`\$HOVIKW]D?]NKP+XBBN6@T?5;Z/0M<0
MG$<UC=.L;EO^N;%)A_M0KVR*_IPI,`HHHI`%?&_[4.N2:W\;-8#LQCLREM&I
M_A"H,C\6+'\:^R*^,OVE],DTKXW:\C@D32K.I[$.BM^F<?45=/<F19^#.C!;
M"XO2N99I/)3UP,9Q]2?_`!VOKC0=)30=%M;.,`+;QA..YQR?Q.3^-?+/PEG"
M^$H&0#=%*^?KNS_+%?5ME=I?V4,\9!CG19%/7((R*)A$EHHHJ"@HHHH`****
M``\UYM\=?V7O#/QWTN9=0M(K;4I$VB\BB4LW'`D4\2+['D=B*])HK2E5G3DI
MP=F;4,14HS52E*S78_,7QU\)/B/^P!\3/[<\)W4]K$QW-$FZ:SU&('E2I^^O
M/*G#IG(/((^ROV/_`-N'PW^U7H@MT,>C^*[2,/=Z5)("7'>2$G[\?KW7(![$
M^K^//`>E_$GPS<:3J]JMS:7`^CQ-V=#_``L.Q_ID5^8/[2?P8U#]GSXMS:UX
M2U"[M]1T.?[2D\4,EM,!U$H1U!!QG<,%6!)&03GZ"DZ>90<:BM477OZ_UZ'V
M>'G0SNFZ=9<M:*TDMGZ_UZ=3]5\CU%%?-?['O_!1+PW\>?#>G:9XCO+30_&K
MS)9-:G(CU*1N%DAZ\,>JG[I]1@U]*9KP:^'J49N%169\AC,%6PM1TJ\;-?CZ
M=T%%%%8G*%?G+_P<6_L.ZW^T?^S]H'Q`\*:?<:IK?PV>X:_L[="\UQILP0RR
M*HY8PO$C;0/N/*?X<']&J,'.::8'\@>._%?67[,/_!;#]H3]EC2K+2M-\71>
M)]`T]%C@TKQ);_VA#$BC"HLN5N%0#@*LH4#H*_6S]LW_`(()?!3]J_6;W7M+
M@O/AQXJOF:6:\T-$^QW4IZO+:-\A)/),1C+'))))-?`'QM_X-F/C7X&\Z?P;
MX@\'^.[5,[(O.;2[V3T^24&(?]_J;:`]K^"7_!TSI\WDV_Q'^%=Y;8QYM]X;
MU%9MWKMMIPF/QG.?;J?M']F'_@L=^S[^U;J=KI>A>-X=%U^\8)%I.OPG3KF1
MCT5&?]U(QZ!4D9N.G3/\_P!\>?V#_C)^S'#-<>._AOXK\/V,#;7OY+)IK!23
M@#[3'NA))]'YKR7Z4^4#^OSOUZ5F^,?!^E_$'PGJ>@ZW8V^IZ/K-K)97MI.N
MZ*YAD4JZ,/0J2*_(/_@WZ_X*H^)-6^)%G\"OB%K-UK=AJ<##PGJ%[*9+BREB
M1G-DSGEHFC4F/<<H4"#(90G['5`'\P7_``4K_8<U/]@/]J;6?!EQ]HN=`N?^
M)CX>OY!S>V$C-LR1QYB$-&_3YD)P`PK%_8J_;G\<_L'>/=9\0^![N**XUS1[
MC2;F&==\+;T/DS;3QYD,NR121SM*GY78']YO^"PO_!/N']OC]EB[M-+MX?\`
MA/?"(DU/PW.1AI7VCS;,G^[.BA1T`D6)CPI!_FWN+>2SN)(9HWBEB8HZ.I5D
M8'!!!Z$'M5+4"34M2N-9U&XO+R>6ZNKN1IIII6+O*['+,Q/)))))/4FOV<_X
M-QO^"=H\$^#Y?CWXKL=NK:]%)9>%(9D&ZULR=LUY@\AI2&C4X!\M6(RLHK\\
M/^"5G[!E[^W_`/M5:7X:FCN(O"&C;=3\37<>5\JS5A^Y5ATEF;$:]P"SX(0B
MOZ7=!T&R\+:%9:7IMK!8Z=IL$=K:VT*!(K>)%"HB@<!54``#H!1)@6Z_FJ_X
M+8_\I1_B[_V$+7_TAMJ_I5K^:K_@MC_RE'^+O_80M?\`TAMJ2`9_P2G_`&)[
M#]OCXE?$KP+/(EMK$7@&[U30+MR0EIJ,5]8")FQ_`RN\;<'"RL0,@5\W^-_!
M6K?#;QCJGA_7M/N=*UO1+J2QOK.==LMM-&Q1T8>H8$<5^A?_``:__P#)_7B_
M_LG]Y_Z<=-KV;_@XZ_X)RBYMU_:!\)61\Z(167C"WA3[Z\1P7W'<?+$_MY1X
MPQIWLP/:O^"`'_!1H_M0_`H_#+Q3?"7QU\.[6..VEE?,FKZ6,)'+SRTD)VQ.
M>X,3$DLQ'AW_``=:'_D@O_<P_P#N+K\O?V9?VBO$?[*'QS\.>/\`PK<?9]9\
M.W0G16)\NZC/RR02`=8Y$+(P]&.,$`U^@?\`P<(_M(^&_P!K;X#_`+,?Q!\*
MW!FTCQ%:Z_-Y;D>;9RC^S%EMY`.DD;AE/8E<C(()+:@?`_['/_)W?PK_`.QP
MTG_TMAK^K6OY2OV.?^3N_A7_`-CAI/\`Z6PU_5K1(`K^=K_@X/\`^4H_C7_L
M'Z7_`.D,-?T2U_.U_P`'!_\`RE'\:_\`8/TO_P!(8:2`X_\`X(G?\I1_A%_V
M$+K_`-(;FOZ5:_FJ_P"")W_*4?X1?]A"Z_\`2&YK^E6A@%?R]?\`!4'_`)2*
M?&K_`+'#4?\`T>U?U"U_+U_P5!_Y2*?&K_L<-1_]'M0@(_\`@GQ^W+JW_!/K
MX\3>/-&T+3O$5Y+I4^E&UO9GBC"RO&Y?*<Y'ECCW-?;?_$4UX_\`^B5^#_\`
MP8W/^%?!G[&'[&/C#]NWXO2^"/!$NC1:S%I\NIL=3N7@A\J-D5AN5'.[,BX&
M/7FOJS_B&E_:*_Y_?AO_`.#F?_Y'IM(#T?\`XBFO'_\`T2OP?_X,;G_"OB3_
M`(*#_MRZM_P4%^/$/CS6="T[P[>1:5!I0M;*9Y8RL3R.'R_.3YAX]A7TI_Q#
M2_M%?\_OPW_\',__`,CU\I_MG_L8^,/V$OB]%X(\;RZ-+K,NGQ:FITRY>>'R
MI&=5&YD0[LQMD8].:$D!N?\`!+[_`)2*?!7_`+'#3O\`T>M?=_\`P=3_`/(_
M_!C_`+!^J_\`HRUKX0_X)??\I%/@K_V.&G?^CUK[O_X.I_\`D?\`X,?]@_5?
M_1EK0]P/RF\.:J-"\0V%^T9E%E<QSE`<%MK!L9[9Q7[$_P#$5/X?_P"B,:Q_
MX4<?_P`CU^..D:9)K6K6ME"4$UW*L$>XX7<S`#/MDU]__P#$-+^T5_S^_#?_
M`,',_P#\CTV!]'_\14_A_P#Z(QK'_A1Q_P#R/1_Q%3^'_P#HC&L?^%''_P#(
M]?.'_$-+^T5_S^_#?_P<S_\`R/1_Q#2_M%?\_OPW_P#!S/\`_(]+0#]IOV-?
MVE(/VP/V9O"?Q)MM(ET&#Q3!+.MA)<"X>WV3R18+A5#9\O/0=:]/KQ'_`()R
M?L]Z]^RK^Q3X"^'WB=]/DU[PU:30W;6,K36Y9[F:4;695)&UQU`YS7MU2!\@
M?\%ZO^43WQ6_[A'_`*>+&OYPJ_H]_P""]7_*)[XK?]PC_P!/%C7\X55$#^CW
M_@@K_P`HGOA3_P!Q?_T\7U?7]?('_!!7_E$]\*?^XO\`^GB^KZ_J0/D#_@O5
M_P`HGOBM_P!PC_T\6-?SA5_1[_P7J_Y1/?%;_N$?^GBQK^<*JB!^Y?[(WQ-N
M/@__`,&T%QK]I,;>\M_#/B*VMI@VUH99]5OK>-U/]Y7E!'N!7X:5^T?PGT"X
M\1_\&L]W;VPW21Z-JMT1@GY(?$-Q,_3_`&4:OQ<IQ`_=S_@V6^#=GX._8K\0
M^,3$IU3QIXBEC>7;@_9K2-8XD]\2/<'/3Y\=N?T@KX4_X-T/%5MXB_X)G:-9
MP,AET'7=2L;@!LE7:47`!X&#LG3CGC!SS@?==0V`5POQK_9D^'O[2$.G1^/O
M!GASQ@FD-(UD-5L8[H6AD"[RFX';NV)G'7:/2NZK!\>_%/PQ\*M/@N_%'B/0
M?#=K=2>3#-JFH16<<KX)VJTC*"V`3@<X%`'E$/\`P3$_9XMYDDC^#'PZCDC8
M,K+HD`92.A!V\&O=:\X_X;&^$/\`T53X;_\`A2V7_P`<KT6&9+F%)(W62.0!
ME93E6!Z$'N*`'4444`%?/7[;?@%O-TWQ)!&2NW[%=$#IR6C8_7+#/^[7T+6;
MXM\+6?C7PW>:5?1F2UO8S&X'5?1A[@X(]Q33LQ-'R5\$;J6YBO[)(Y9%A`N/
ME4L$'"DG'3G;7TC\%O%2ZKH1T^5Q]HL?N@]6C)X/X'C\J\R^#?A.^^`6E_$G
M4M0C!FT&P,L#C(2X1(Y9=PXZ':GK@Y'45E?#7]JZQU=;/5-1TB"5V&[[78'R
M9?0ATSM8]CR*^<SSB[+<JQ%/#X^;BYIM.S:TTUM=J_I;NS)UHQDH-ZO4^F**
MY;P?\:/#7CC8ECJD`N'X%O.?*ESZ`-][_@.:ZFO7P>/PV+IJMA:BG%]8M-?@
M:II[!11176,****`"BBB@`KD_BY\)](^*WA6XM=1TJVU"YCB<VC/(8)$DP=H
M$H5B@)QGY6'JK=*ZRC-5&<HOFB[-&E*K*G-3@[-?UT/RW_86\.>%/%W[:UC?
MZ-JD5C'X2N+V;7/#NK/'::UH%Q!%*CH\.2)HDFP/-@+J!C<(R<5]^?LA?M2^
M'/VS?V?/#WQ#\+M+'I^MQ'S;64@S6%PA*RV\F/XD<$9Z,-K#A@:_'S_@OA\%
MC\)OVZ+GQ'HDDNG3>*]*MM>66U<Q/#<*7MI2"N"&;R0Y(ZF0GKFNM_X-M?VF
M;CP%\<O$GPFO[ESI/C.U;5=+B9LK#?VR$R!1V\RW#%CS_P`>R>]?/2XGQ%?'
M1PN+M>-XW77^5V[OKZG](<5^&-+'<+_ZV9?4<DZ=.HH/[,5S>UC?[7*W=.R:
M4&G=NY^T5%%%>^?S6%?B9_P5>_X*O_M)_LJ?M\^/?!/A;Q^=$\,:9):2Z7:?
MV#IEP$AELX)<B2:V9V^=WR2QP01VK]LZ_,K_`(.#?^"8^L_M'^'M/^+_`(!T
MV75/%/A6Q-EKFF6R;I]2L$9I$FB4<O+"6<%>6=&&.8PK-`>%?\$E_P#@M1\8
M/B]^W!X7\'_%WX@P:MX6\5)-IL$<NCZ?9)'?,F;8^9!#&^7D41`9(+2@8Z$?
MM57\@T<DEI<*Z,\4T39#`E61@>OL0:^[OV;_`/@X@^/OP)\-6>BZS)X?^(FG
MV2+''/K\$IU!4&,*;B)T,AQ_%*'8YY)IM=@/Z"+BWCO+>2&:-)8I5*.CJ&5U
M(P00>"".U?SW_P#!P3^S5X%_9M_;:LH?`MA8Z+;>)]"BUC4-*LU5+>RN6GFC
M+1QKQ$KK&K;```=Q&`<#O_B1_P`'._QG\2Z3+;>'/"'@/PS+,NW[6T-Q?3PG
MGYD#R"//3[R,..ASQ^?OQ?\`C%XH^/OQ$U/Q;XRUN^\0^(M7D\R[OKI@7D(&
M````JJH``50%4`````4D@/2/^":JW[?\%"?@F--,GVC_`(3;22VP@'R?M<?G
M=>WE;\^V:_J.K\5?^#=G_@F_K7B/XJ6WQY\6:;<:?X=\/QRQ^%X[B)D;5;J1
M&C:Z4$?-#&C.`PX,A&#F,U^U5#`*_D;^(?\`R/\`KG_80N/_`$8U?UR5_(W\
M0_\`D?\`7?\`L(7'_HQJ<6!^IW_!JQ_R/_QGZ?\`(/TK_P!&W5?LM7XT_P#!
MJQ_R/_QG_P"P?I7_`*,NJ_9:DP"OYJO^"V/_`"E'^+O_`&$+7_TAMJ_I5K^:
MK_@MC_RE'^+O_80M?_2&VH0'O'_!K_\`\G]>+_\`LG]Y_P"G'3:_<WQ7X5TW
MQUX7U'1-8LK?4M(U>UDLKVTG0/%<PR*4>-@>JLI((]#7X9?\&P'_`"?SXO\`
M^R?WG_IQTVOW=HEN!_,;_P`%/?V#M3_X)_\`[46J>%G2>?POJ9;4?#=^_/VJ
MR9CA&;O+$?W;],E0V,.N?!KKQ=J=]X3L="FO9Y-(TR[N+ZUM"V8X)ITA2:11
MV+K;P`_]<UK^D[_@K!^P#8_\%`/V7+_1+>&&/QKX=$FI>&+ML*4N@OS6[,>D
M4ZC8W8,(W.=@%?S5Z[H=[X7UN]TS4K6>QU'3IWMKJVG0QRV\J,5=&4\AE8$$
M'H0:J+`[S]CG_D[OX5_]CAI/_I;#7]6M?RE?L<_\G=_"O_L<-)_]+8:_JUI2
M8!7\[7_!P?\`\I1_&O\`V#]+_P#2&&OZ):_G:_X.#_\`E*/XU_[!^E_^D,-)
M`<?_`,$3O^4H_P`(O^PA=?\`I#<U_2K7\U7_``1._P"4H_PB_P"PA=?^D-S7
M]*M#`*_EZ_X*@_\`*13XU?\`8X:C_P"CVK^H6OY>O^"H/_*13XU?]CAJ/_H]
MJ$!](?\`!M+_`,I%+W_L3[__`-'VM?OK7X%?\&TO_*12]_[$^_\`_1]K7[ZT
M2W`*_`K_`(.6O^4BEE_V)]A_Z/NJ_?6OP*_X.6O^4BEE_P!B?8?^C[JB.X'S
M?_P2^_Y2*?!7_L<-._\`1ZU]W_\`!U/_`,C_`/!C_L'ZK_Z,M:^$/^"7W_*1
M3X*_]CAIW_H]:^[_`/@ZG_Y'_P"#'_8/U7_T9:TV]0/RQ^'G_(_Z'_V$+?\`
M]&+7]<E?R$65[+IUY#<0.T<T#B2-QU5@<@_G7T5_P]X_:7_Z+'XP_P"_T?\`
M\31(#^FVBOYDO^'O'[2__18_&'_?Z/\`^)H_X>\?M+_]%C\8?]_H_P#XFE8#
M^FVBOR/_`.#>W]M_XL_M0_M,>-=(^(/CO7?%>F:?X8-Y;6]](K)#-]K@3>,`
M<[68?C7ZX4-`?('_``7J_P"43WQ6_P"X1_Z>+&OYPJ_H]_X+T_\`*)[XK?\`
M<(_]/%C7\X5.+`_H]_X(*_\`*)[X4_\`<7_]/%]7U_7R!_P06_Y1/?"G_N+_
M`/IXOJ^OZD#Y`_X+U?\`*)[XK?\`<(_]/%C7\X5?T>_\%Z?^43WQ6_[A'_IX
ML:_G"JHL#^A[_@C9\.;#XP?\$3O!GA+559M+\4:7X@TF[``)\J?4]0B?&>^U
MC7X#_&;X3:S\"/BQXC\&>((#;:SX8U";3;M,':7C<KN7/5&`#*>ZL#WK^A?_
M`((+?\HGOA3_`-Q?_P!/%]7A_P#P71_X)"7_`.U#!+\7/AI8_:?'>EV@BUG1
MH8\R^(+>,822+'WKF-?EV]9$"J/F55=)V`^4O^#>#_@H+I/[-7QAUGX9^,=2
MBTWPQ\098IM.N[APEO8ZH@V!7)X59TVIN/1HHAP"2/W<K^0F_L)]+OI[:YAF
MMKFV=HI894*21.I(96!Y!!!!!Y!KZI_9O_X+6_M$?LR>&[30]*\:#7M"L$6.
MVL/$%HFH+`B\!%E;$P0``!1)M`&`!3:`_I-K\,/^#DO]L[3/C5\??#WPP\.W
ML-]IWPX2>35IH6#1MJ4VT-#D<$PQH`<'AY9%(RE>-_';_@O+^TA\=?#-QH[^
M++'PEI]XACN!X<L193R+W`G)>9/K&Z_E7QP6>XF+,7DDD;))Y9B3^I)H2`[;
M]FCX*WW[1O[07@SP+IR2-=>*M7M].W)UBC>0"20^R1[G)[!37]7]E9Q:=9PV
M\"+%#`@CC0=%4#`'X"OR\_X("?\`!*75?@.@^-?Q&TR33O$VJ6;0>&M*N$*S
MZ7;2KB2ZE4\I+*AVJAY6-GW<OA?U(I-@%%%%(`HHHH`\K_;6\0?\([^R]XNF
M!.^>V2T51]YS+*D>!Z\,?PK\_O!7C>^^&.L&SU2VN[:VGVO+#-&R21A@"L@4
MC/((/N,>U?JE+`LI7>BOM8,,C.#Z_6O,OVEOV5]`_:1\/^7?(+#6K5"MEJ<2
M`RP]PC_WX\_PGIDD$$FOS+CW@>OG4EBJ%3WH124&M'JV_>OHW=6TMIJ]=/(S
M#`U:DU6I2LTM%W/E>PUBWO8X+J(Q75L^'&&.R1<],CD9Z<<U]:?`;XN>'?&N
M@0:=IC&PO+5,-83SM)(!W*,Q)=??J.X%?GUX[\(^-/V1?%K:7X@L9'TZ=R89
M4):UNP/XXGQPWJIP1W'0UTWA7XB6NOQQ7NE7CQSPD.-CE)H&'0G'(/H1^!K\
M=X<SK&\+XZ?/2NGI*+5I?)VNOR?;9KDP^9<LG&:M);I_H?I'FBOE7X5?MRW_
M`(>$5EXIMWU2U7Y1>0@+<H/]I>%?]#]:^A?A_P#%[PY\3[59-$U6UO'V[F@W
M;)X_]Z,X8?7&/>OZ(R+B_+,VBOJU2T_Y9:2^[KZJZ/8H8RE5TB]>W4Z6BBC-
M?3G4%%&:*`"HYED:%Q$Z)(5.QF4LJG'!(!&1[9'X4AU"W%\+4SPBZ:,RB'>/
M,*`@%MO7&2!GIDUYM^U/^U7X7_9.^'-SKNOW*R7;HPT_3(G'VG49>R(.R@D;
MG/"CU.`>C#82MB*L:%"+E*6B2W9Q8[,L-@L//%XJHH4X*\FWHO7_`"Z['Y`?
M\%=_V@]?^/7QKL]%\6>&H/#7B7P!:3Z-J4<$AD@O)#(76XA+?,(I(RCJK9(#
M?>;.:\!_X)\^*)OAG^W-\)=7@D>$1^*;"VE=<Y$,\RP2CCKF.1QCO7U)^V.]
M[^WI^SK:_&33](CD^('AF]_X1[QA8:;"Q,MO-(387:QC+;0&,!/+,P'9:\C_
M`&8/V!_CW>?%#PQXHT#X2>(;L^'M4M=5B368?[*M;KR9DE"E[AH\HVW!*G."
M<<U^8\1Y/F&6YY/"8F+<X26J5[K2ST6NG4_T3\,.->$N(_#&AC\!5IT:%2E.
M'+*:BHS:?/&\Y:>\[I-NR:3/Z`\T5@?#/7==\2^"+"]\2^'U\,:W.F;K34OD
MODMGST$R`!QWS@?2M^OT2,KI-'^?U:E*E4E3E9M-K1IK3LTVFNS3:?1A1^=%
M%49'R;^V-_P1;^!G[96JW6M:GH-QX4\5799Y=9\.R):37+G^.:(JT4I)Y+%-
MY_O#K7Q1XZ_X-6[^.ZFD\,_&2TFA;F*'4_#[1.G(X:2.=@W&3D(.PQWK]B:*
M:8'XS^%_^#5SQ'<W*?VU\8M$LH0WS?8M`EN6*X[;YHQDGCVZ\]*^I?V7/^#>
M'X$_`'6;75_$<>K_`!,U>U99$76V1-.1P<AA:Q@!Q_LS-(OM7WG11<"*RLX=
M.LXK>WABM[>W01Q11J$2-0,!5`X``&`!TJ6BBD`5^:>M_P#!L1\)-=UF\OI/
M'_Q&22\F>=E5K+:I9BQ`_<=.:_2RBG<#Y:_X)U_\$I?!O_!-W6?%5]X5\1^)
MM=D\60VT%RNJF`K"(6D92GEQKR?,.<YZ"OJ6BBD`5\&_M8?\$`OAM^US^T+X
MF^(VM>,_'&F:IXHGCGGMK(VHMXBD,<0"[XF;&(P>2>2:^\J*`/CW_@GW_P`$
M:/`G_!._XRZGXV\,>*?%NMZAJFBRZ))!JAMS"D4D\$Q<>7&IW!K=1UQACQTK
M["HHH`*^&_VR/^""GPI_;'^/6J?$&^UOQ3X6U77(XSJ%OI!MUM[J=1M,Y$D;
M$.RA0V#@E=W4DG[DHH`_.;X7_P#!M?\`"KX5?$SPYXHLO'?Q!N;OPWJ=MJD$
M4S6?ERO!*LJJV(0=I*`'!!QFOT9HHIW`*^(/VUO^"%7P\_;A_:%U;XC>(/%_
MC32-4U>&W@DMM.-L+=!#"L2D;XF;)"`G)ZU]OT4@/@W]D_\`X(!?#;]D;]H7
MPS\1M%\9^.-3U3PO/)/!;7IM3;REX9(B&V1*V,2$\$<@5]Y4447`*_/G]H/_
M`(-V?AA^T3\;_%?CO5/&_CRQU'Q;J<^J7%O:FT\F%Y7+%4W0EMH)XR2:_0:B
MBX'QG^P7_P`$4_`7_!/[XX2^._#7BOQ?K6HS:9-I9M]3-L8`DKQN6_=QJVX&
M,8YQR:^S*,T4`%?&?[>G_!%/P%_P4!^.$7COQ+XK\7Z+J,.F0Z6+?3#;"`I$
M\CAOWD;-N)D.><<"OLRB@#\^?V?/^#=GX8?L[?&_PIX[TOQOX\OM1\):G!JE
MO;W1M/)F>)PP5]L(;:2.<$&O8?\`@HI_P2E\&_\`!2+6?"M]XJ\1^)M"D\)P
MW,%LNE&`+,)FC9B_F1MR/+&,8ZFOJ6BG<#\R?^(7+X0_]%"^)'_?5E_\8H_X
MA<OA#_T4+XD?]]67_P`8K]-LT47`_,G_`(A<OA#_`-%"^)'_`'U9?_&*/^(7
M+X0_]%"^)'_?5E_\8K]-J*+@?(__``3U_P""/G@C_@G1\3-;\4>%_$_BO7+O
M7-,_LN6+5#;F*-/-27<OEQJ=V8P.3C!-?7%%&:0'F/[8W[+FD?MH_LX>(_AI
MKVHZEI6D^)?LWGW5AL%Q%Y%U#<KMWJR\M"H.0>">^#7PO_Q"Y?"'_HH7Q(_[
MZLO_`(Q7Z;9HIW`\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NI
MKEMVQ57AIF`P!P!WR:].HHI`>8_MC?LN:1^VC^SAXC^&FO:CJ6E:3XE^S>?=
M6&P7$7D74-RNW>K+RT*@Y!X)[X-?"_\`Q"Y?"'_HH7Q(_P"^K+_XQ7Z;447`
M\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NIKEMVQ57AIF`P!P!
MWR:].HHH`^9OVS?^"1_P3_;@O9]5\4>')-(\53+M/B#0Y19W\F!@&7AHICT&
M949@``"!7PM\0_\`@U<F%Y++X3^,436[$^7;ZMH!#QC(P#+%-AN,\B,=!QSQ
M^P5%-,#\;?!G_!JWK<]VA\0_&+2K2W5_F33M`DN'=>.`TDR!2>><'&!US@?:
MO[&7_!$KX'_L::S::]::1=^,O%MDPDAUCQ`Z7#6D@_C@A55BC(."&*LZXX?K
M7U[10V`?G11FBD`4444`%%%%`!1110!C^-_`6C?$GPY/I&O:;::KIMR,/!.F
MY<XP&'=6&>&!!'8BOB?]H'_@EQKOA#4)=<^%VHRWL29?^R[F81W47?$4IPL@
M[;7VG`ZN37WA17A9UPW@,TARXJ%VMI+22^?Z.Z\CCQ>`HXA6J+7NMS\BI/B]
MJO@76I-&\8Z1?:;J-J=DOF0&&5/=HVQ^8X]!73Z'XYM-6*7.E:@CRQG<K0R%
M9(SZX^\IK](_BK\#_"7QOT8V'BK0-.UJ``A&GCQ+#GO'(,.A]U(KY'^,7_!&
M33KVXEO?A_XKNM'GSNCL]44S1`YZ+,F'11[JY]Z_(,U\+<71DZF!ESK[G]ST
M^Y_(^;Q638J&M)\Z^Y_Y&!X._;1^('@-4C36!JMM'TAU&,7&?^!\2?\`CU>D
M>'_^"GTUN%36/"<4I'WI;.]*#\$=3_Z%7RC\0/V0_P!H7X*N_F>'+WQ+8QG"
MS:;C4Q)COM3]^!_O**\EUGX[ZWX3U!K/7?#DMG>)]^&426LB_P#`7!(KSZ.8
M\397^[=2:2Z25_NYT_P/'J9CF.&TO)>J_P`S]+;7_@J%X)\K-UH?BF)_2**"
M0?F95_E71_"']N[P[\<?B-9>&]`T/Q'Y]RCRR3W4<,<5NB*26;;(YQT`]2P'
MO7Y0S?M-V94EM+NE;T$JD?R%>R_L2_\`!2/P-^S]XCUV7Q'H?B**76;=+2#4
MK`0SO8IDELQN5R"VTD@G[@^4U]-DG%^;U\93IXR<84[^\^5;?+OMMH:8/B/&
MSKQC6DE"^KLNG3Y['H/[7?[4^OV_[9FH^(/"6KRZ?)X6A;0K.6,+(CJN1/E&
M!1P92Y&01\B'J!CYD^-/CBY\57USKGBO6+S5]1G',MU*9II`,X5<GA1G@#"C
MVKVB+]G+1/V@;MYOA'\7_"'BBXNR7_LK52VEZT6)^Z(YL^:V>K`*,_45X)\?
M?V7O'?P:OV/B_P`/:SI<;L$-[<Q-+;'G'$R;D;'HI)K^^N$L5D.*P]/^S:\)
MRC%1TLI-+UL][OU9_%O%^6<73QU;$Y[2J1H5*DJGNR<Z:<NTHMTTU&ROO96/
M(O`7[8GQ(_9B^(.K>(OA]K;^'+O4[)M.D'V>&Z3R2ZN#LE5D+AE!#;<C)`X)
M%?JG_P`$=?AA\:O$/AS4OBS\;?&/B[5=0\4VX@\/Z'J-VZ6UG9EE=KLVHQ&D
MDI"A/D#+&I/23`SOV'?^"-?@CP0^C>.O&VHZ9X_U*2..^TZVM1OT:$,`Z2Y/
M-SQ@@L%3G[AX-?>1SZ5^=\=<58'%2EAL!33D])5''5V^RFU>W=_):']7>%W!
M689=AZ=;,)N,(J\*2E=*_P!J23Y;]EKKJ]=!:***_+S]H"OSR_X+.V%MXO\`
MVO/V3_"FL>(]8\.>%?$^J:Y;:S+8ZL^F;X@NGD%I58`8).">FX^M?H;7YR?\
M%L=*\%ZY^V?^R#:?$1]$C\$W&K:\NL-J]PEO8B#9IN?-D=E55SCDD4`><?M^
M?`/P!^Q7\%D\??!#X[>/8?BA8ZG8V^@Z)!XV.L#Q!))=1H\!M<L\G[MV<KRI
M";2IW5^J'@V[U'4/"&DW&KVZ6FJSV<,E[`ARL,Y0&1![!LC\*_+'_@H=\.OV
M(/AY^R]XA\1?#/Q!\/-(^)FC1K/X6N?`WBA9]4CU`.#%A+:=CL)X9V7"C)!#
M`&OTA_93OO%6I_LQ_#RY\<QRQ>,[CPWI\FMK*-LJWAMHS-O&!A]^[<!P&R!Q
M3N!W]%%%(`KY,_X+E^(=0\*?\$M?BCJ&EWUYIM];_P!D^5<6LS0S1YU>R4[6
M4@C*D@X/()%?6=?('_!>K_E$]\5O^X1_Z>+&@#ZI\`2-+X$T1W9G=["`DDY)
M/EKS6M6/\/?^1`T/_L'V_P#Z+6MB@`HHHH`^;?\`@JS^UUK'[&O[(FH:]X6@
M2?QIXBO[?PWX<5E5PM]<EMK[6X8I&DKJI!!95!&W->5^"?\`@AWX.\2>`H+W
MXG^-OB9XN^)VHVZ3:GXD7Q1<Q/;79&2;9<[0B,<)YBMPHX'0=+_P6\^!GB7X
MQ_L70:IX1T^;6-?^&OB2Q\9V^G1(9)+U;42I(@4<MMCG=]HY(C(&3@'T3X,_
M\%//@;\9O@S9^-8/B3X/T6REMEFO;35=7@M+S2Y"N6AFC=@P=3D<`AL94L""
M0#RC_@F9\:O'7@?]H#XK?LV_$KQ#=^,=9^%OV?4/#_B&[RUWJND7"JR?:&)R
MTD8DARQ+',CJ6.P$_:E?!'_!-#6[K]KO]O?XX_M&Z?:W=I\/]5M;7P=X5FN(
MFB.KQ6_EF:Y"L`P7?"I&0/\`7%3\R-7WO0`4444`%?$'_!+#Q3JFO_MD?MAV
MU_J5_?6VF^/(XK2*>X>1+5-UW\L88D(.!P,#@5]OU^;W_!.[]HWX>?`G]MW]
ML2'QQX\\&>#9=2\?*]HFN:W;:<UTJ/=AC&)G7>%++DC.,CUI@?I#17%?"S]I
M7X<_'/4+NT\$>/\`P3XQN[",2W,.AZY:ZA);H3@,ZPNQ52>,G`S7:T@"BBB@
M#-\9>+++P%X0U77=2E\C3M%LYK^ZD_YYQ1(7=OP52:_.C]CG]D_4?^"MGA&Y
M^.OQU\1^,)M"\4:A<_\`"(^#=,UF:PTS2+"*5X5=A$59I2RN-P*E@H8E@X"_
MH3\6?`<?Q3^%GB;PQ+*8(O$>E76EO*!GRUGA>(M^`;-?#W_!'O\`:X\+?`_X
M!+\`OBAK6D^`?B;\)KZ[TNZT_6KI+%=0@:X>:*XMWE*K*A67`VG)"A\;64D`
MH6_AS7?^"2'[;GPN\,Z)XL\2^)?@=\;=0/AU=%UV_:^E\,ZH2JP-;2-R(W:1
M!M[C?NW,$(_1"OSO_:@^-6C_`/!0_P#X*)?`GX;?"[5+7Q3HGPD\1Q^/?%VN
MZ;(MQIUBUJR-;P+.N4=V8,A"DX,JC.5?;^B%`!1110`5\2_\%&/BCXZ^-7[5
M_P`./V8OA]XEO_!!\9Z;-XD\7^(;`F._LM(C=T6*W<'*-*\,J$CG)C!PA<'[
M:KX`_;O\1K^Q#_P5'^%_[0>NVMROPU\1^'9?`?B34X8FE7193,\T$\H`)",6
MC'R_PP28!;`8`O?%C_@B1X=\$?#2[UCX*>+_`(C^$/BMH=NUUH^K-XFGF&I7
M*#<(;E781[)2-I*A5!;)#*"A^NOV;=0\;ZI\"/"LWQ)T^TTOQX=/C37(+:6.
M6'[4ORNZ&,E-KXWX4D+OQVKXJ_X*-P?LB^/_``UK'Q4\1^,+3Q9XLO-+6WT7
M3_#7C29[G6)@C+;10VUK-R6<@%]N!G+&O4_^"$NHW&J_\$J?A9<75Q-<W$G]
MK;I)7+NV-8O0,D\G@`?A0!]<T444`%>>?M=7DVG?LH?$^YMYI;>X@\):K)')
M&Q1XV%G*0RD<@@\@BO0Z\X_;&_Y-$^*G_8GZM_Z134(#S_\`X).ZS>>(?^"<
MOPBO;^ZN;Z\N=!1Y9[B5I993O?EF8DD^YKZ'KYP_X)"_\HTO@Y_V+Z?^C'KZ
M/H`****`//?VL/CU;?LO?LV>-_B#=0"[3PGI$]_';EBHN9E7$41(Z!Y"BY[;
MLU\:?LJ?\$PHOVS?@OHOQ7_:)\5^.O%WC;X@6::S#80:Y<:?I_AZVN!YD$-O
M#"RA#Y1C9E/`8[=N06;ZG_X*'?`C4/VF?V)/B7X'TF,2ZOKFBRC3XB=HFN8B
M)H8\Y&-TD:KD\#//%>._\$S?^"C7PR\??LB>$-&\1^,/#G@WQEX$TJ#P_P"(
M-&UV_BTR[M+BSC6!I/+F924;8&R,A22IPRD`N!M?L'?L\?%[]DCXW>.?`VM:
M]JWC?X(FWBOO!NLZUJ276IZ;+E1)8."?,*`,V#M"?N00$+E:^KJ^4?V/_P!N
MK7?VS/VS/B7:>$8],U'X%>!]/BTZSUZ.U</JVLLT;/Y,Y;;)"B"4$*O>)L[7
M7=]74`%%%%`!7Y5Z_J7@;]KC_@IC\9?"/[2WQ'UCPEIG@N[M[+P/X4GU^30=
M+O+4JY:Z\P,@DF<>4X^8,1+CYU4*GZJ5\$I^T)\$?VO_`(\?$CX4_M,>#/AO
MX=\:^`];ELM#;7'2W?5M*/,$]M=2['#./G,:.,JZ$`X;#0':_L7_`+(OC?\`
M9$_:DU:U\'>*K[Q7^SAXDT-;NPM]4UK^T)]#U,2?<MR22860,21U\Q<Y*%C]
M@U^7?[,7A;P'^SG_`,%@_"/@G]FKQ5=ZO\./$/A_4+_QWH>G:NVL:-H[1PR?
M9YA*7<+(9A;J=S,R[PN<2;1^HE(`HHHH`****`"BBB@!"X!QS33,!GC-(V<'
MUJ"0D+R:`)C=*.H-,.H(O4&JD^XIE2`?>L+6FU((WV::W0]1N4F@#ICJD8[$
M_C5+7++3/$UF;;4K"SU"W/)BN85E3KZ,"*\F\63^/\L-.U?0X2.GFV[L/TKE
M;*;XQ"]S-XC\(-`3PJ6$P8#ZEJ;A=69+:>AZ+K/[(OP@\1S^;>?#+P+)+G)=
M=$MD9N,<E4!/`[UEV_[`_P`$(IY95^&'@]GF.6#V*.HY[*V0OX`5<\*S>,"%
M%_J6E3-CGRH64?K7<:6;LJOG21,?]D$5R2R_#-W=./W+_(Q>%H2U<%]R,OP5
M^SS\._AW<1R^'_`G@_1)XB"LMCH]O;R`@#G<J`D\#G.>*[.Y@AO[>2">*.:&
M52KQNH97!Z@@]156(G`R>:G0G`]*WITXP5H*WIH:QIQBN5))$/AWPWIWA+28
MM.TFPLM+T^`L8[:T@6"&,LQ9B$4`#+,S'`Y))ZFK],7[PI]:2DVVV[MCA!1B
MHQ5D@HHHI%!7'_%;]GKP!\>/L'_"<^!_!_C/^RO,^Q?V[HUMJ/V/S-OF>7YR
M-LW;$W;<9V+GH*["B@#S#PI^Q)\&/`?B&TU?0_A%\,-%U:PD$MM>V/A:QM[B
MV<=&21(@RL/4$&O3^E%%`!1110`5C^/?AYH'Q4\)W>@>*-"T?Q)H5_L^U:=J
MEE'>6EQL=9$WQ2!D;:ZJPR.&4$<@5L44`,M[:.TMXX88TBBB4(B(H544#```
MZ`#M3Z**`"BBB@`&>>*\4\:?\$W_`("_$/QO)XDUKX1^`]0UF>0RS7$FE1#[
M2YZM(@`61CW+@DU[710!4T'0+#PKHMKINEV5IING6,:PVUK:PK#!;HHP$1%`
M"J!T`&!5NBB@`HHHH`*\N\4?L/\`P6\;^([W6-;^$'PNUC5]3F:XO+Z]\*V%
MQ<W4K'+222/$6=B>22237J-%`'$_"S]FKX<_`S4+J[\$^`/!/@ZZOXQ#<S:'
MH=KI\EP@.0KM"BEE!YP<C-=M110`4444`%>;?'7]COX6?M-2V\OC_P``^%_%
M5S:+LANKZQ1[F%,YV+,`)`N>=H;!]*])HH`Y+X._`;P5^SYX:;1_`WA3P_X2
MTR1_,DM]+L8[99GQC>^P`NV.-S9..]=;110`4444`%4/$WA?3?&F@7>DZSIU
MAJ^E:A&8;JSO($N+>Y0]4>-P593Z$$5?HH`\=^&7_!/GX(?!GQROB7PO\*_!
M.BZ]$WF0WMOI<?FVK?WH<@^4>V8]IQ7IG@CP'H?PS\,V^B>&]%TGP]HUFTC0
M6&FVD=I:PF21I'*QQ@*I9W=C@<LQ)Y)-:U%`!1110`56UG1K/Q%I%WIVHVEM
M?V%_"]O<VUQ$LL-Q$ZE7C=&R&5E)!!!!!(-6:*`,SPAX-TCX>^&K+1=`TK3=
M#T;3H_)M+#3[9+:UM4SG:D:`*JY)X``YK3HHH`****`"O(OC!^P/\%OC]XM&
MO>,OACX.U_6R07O[C3D%Q/MZ"1U`,@`&`')&.*]=HH`QO`/P[T#X5^%;70O#
M&B:3X>T6Q&VWL--M$M;:$$Y.V-`%&3R>.36S110`4444`%>=_'/]DCX8_M,Q
MVX\?^`_"_BR6T&V"?4+!)+B!<YVI+CS%4GD@,`:]$HH`XGX)_LW>`/V;]#FT
HWP%X.\.^$;2Z*M<+IEC';M=%1A6E91ND8#/+DGFNVHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
